Stockscreener 앱 받기
0.8977
1.07%
-0.0097
시간 외 거래:
.92
0.0223
+2.48%
전일 마감가:
$0.9074
열려 있는:
$0.9039
하루 거래량:
3.51M
Relative Volume:
2.32
시가총액:
$170.15M
수익:
$8.95M
순이익/손실:
$-21.49M
주가수익비율:
-7.4808
EPS:
-0.12
순현금흐름:
$-29.24M
1주 성능:
-16.88%
1개월 성능:
+35.05%
6개월 성능:
+78.65%
1년 성능:
-5.91%
1일 변동 폭
$0.85
$0.9575
1주일 범위
$0.85
$1.10
52주 변동 폭
$0.3651
$1.15
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
명칭
Lineage Cell Therapeutics Inc
전화
510-871-4188
주소
2173 Salk Avenue, Suite 200, Carlsbad, CA
LCTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
0.8977 | 170.15M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 개시 | Craig Hallum | Buy |
| 2022-11-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-14 | 개시 | B. Riley Securities | Buy |
| 2021-08-19 | 개시 | Noble Capital Markets | Outperform |
| 2021-03-31 | 개시 | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Two Sigma Investments LP Buys New Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Rising Demand in Allogeneic Stem Cells Market USD 2.0Bn By 2031 - openPR.com
Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Cell Therapy Manufacturing Market Exclusive Report with Detailed Study Analysis | WuXi AppTec, Healios Ltd. - newstrail.com
Lineage Cell Therapeutics appoints new auditor - Investing.com Australia
Two Sigma Advisers LP Has $44,000 Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Jane Street Group LLC Buys 142,965 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace
Deutsche Bank AG Has $87,000 Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Future of Personalized Treatment: Stem Cell Therapy Market - openPR.com
B. Riley Predicts Lineage Cell Therapeutics FY2029 Earnings - Defense World
Transcript : Lineage Cell Therapeutics, Inc. Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 02 - marketscreener.com
Spinal cord injury Pipeline 2025: Groundbreaking Clinical - openPR.com
Cell Therapy Manufacturing Market Is Booming Worldwide | WuXi - openPR.com
Lineage Cell Therapeutics Q2 EPS Lowered by HC Wainwright - Defense World
Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans - MSN
Comerica Bank Boosts Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Barclays PLC Acquires 22,769 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Inve - GuruFocus
Lineage Cell Therapeutics Q1 2025 Earnings: EPS Beats Estimates at -$0.02, Revenue Misses at $1.5 Million - GuruFocus
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Business Wire
Wells Fargo & Company MN Increases Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus
Lineage Cell Therapeutics Reports Q1 2025 Financials - TipRanks
Lineage Cell: Q1 Earnings Snapshot - Huron Daily Tribune
Lineage Cell Therapeutics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook - Nasdaq
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025 - Business Wire
Cell Therapy Manufacturing Market Projected To Witness Massive - openPR.com
Lineage Cell Therapeutics announces cGMP production success - Investing.com
Lineage Cell Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - BioSpace
Lineage Cell Therapeutics announces cGMP production success By Investing.com - Investing.com Nigeria
BlackRock, Inc.'s Strategic Acquisition of Lineage Cell Therapeu - GuruFocus
LCTX (Lineage Cell Therapeutics Inc) has impressive results - uspostnews.com
Lineage Cell Therapeutics (LCTX) to Release Earnings on Thursday - Defense World
JPMorgan Chase & Co. Raises Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Upward Trajectory: Lineage Cell Therapeutics Inc (LCTX) Posts a Gaine, Closing at 0.47 - DWinneX
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Shares Bought by Renaissance Technologies LLC - Defense World
Lineage Cell Therapeutics Inc Inc. (LCTX) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Lineage Cell Therapeutics Inc [LCTX] Shares Rise 5.57 % on Thursday - knoxdaily.com
Stem Cell Therapy Market Growth, Trends, & Key Insights | Global - openPR.com
Lineage Cell Therapeutics Inc (LCTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Lineage Cell Therapeutics Inc 주식 (LCTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Howe Jill Ann | Chief Financial Officer |
Nov 26 '24 |
Buy |
0.59 |
15,000 |
8,850 |
25,500 |
| Samuel George A. III | General Counsel |
Nov 26 '24 |
Buy |
0.60 |
15,000 |
9,000 |
22,184 |
| Mulroy Michael H. | Director |
Nov 22 '24 |
Buy |
0.57 |
40,000 |
22,640 |
298,555 |
| Culley Brian M | President and CEO |
Nov 21 '24 |
Buy |
0.60 |
40,000 |
24,000 |
194,842 |
| Howe Jill Ann | Chief Financial Officer |
Aug 16 '24 |
Buy |
0.89 |
10,500 |
9,345 |
10,500 |
0.39%
0.42%
자본화:
|
볼륨(24시간):